CD8A and neoplasm: These data demonstrate that 5‐FU/cisplatin combined with ICB enhanced activation of intratumoral CD8+ and CD4+ T cells, and the anti‐tumor response for these chemo-immunotherapy combinations were dependent on CD8+ T cells.